| Bioactivity | Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC) is a potent 12/15-Lipoxygenases (LO) inhibitor. Cinnamyl-3,4-dihydroxy-α-cyanocinnamate has the potential for the research of type 1 diabetes mellitus[1]. | ||||||||||||
| Invitro | High glucose or 12(S)-HETE remarkably increased transendothelial dextran transport, and in combination it was increased further. Addition of the 12/15-LO inhibitor, CDC, partially suppressed dextran transport[1]. | ||||||||||||
| In Vivo | The high glucose and 12(S)-hydroxyeicosatetraenoic acid (HETE) could alter vascular endothelial (VE)-cadherin and β‐catenin phosphorylation levels, but did not alter total protein expression. However, the 12/15-LO inhibitor, Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC), antagonized the effect of high glucose on protein phosphorylation to mitigate destruction of the endothelial cell barrier, and the mouse diabetes mellitus model further confirmed these conclusions[1]. | ||||||||||||
| Name | Cinnamyl-3,4-dihydroxy-α-cyanocinnamate | ||||||||||||
| CAS | 132465-11-3 | ||||||||||||
| Formula | C19H15NO4 | ||||||||||||
| Molar Mass | 321.33 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Wang X, et al. 12(S)-hydroxyeicosatetraenoic acid impairs vascular endothelial permeability by altering adherens junction phosphorylation levels and affecting the binding and dissociation of its components in high glucose-induced vascular injury. J Diabet |
Cinnamyl-3,4-dihydroxy-α-cyanocinnamate
CAS: 132465-11-3 F: C19H15NO4 W: 321.33
Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC) is a potent 12/15-Lipoxygenases (LO) inhibitor. Cinnamyl-3,4-dihydroxy-α
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.